Life Sciences

Mintz advised the former shareholders of biopharmaceutical company Censa Pharmaceuticals, Inc. in the sale of their sepiapterin earnout royalty rights back to PTC Therapeutics, Inc. (NASDAQ: PTCT) in accordance with a Rights Satisfaction Agreement.

Mintz advised the lead placement agent in connection with an up to $50 million private placement by Equillium, Inc.

Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.

Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share.

Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share.

Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.

Mintz represented Granata Bio Corporation, a biopharma company focused on invigorating the $3.6 billion global infertility medication market, in its $15 million Series A+ funding round.

Mintz advised Relation Therapeutics, an industry leader in deploying computation and experimentation to drug discovery, on an equity investment of $15 million from GSK in connection with two simultaneous strategic collaborations with GSK, a global biopharma company. The collaborations are aimed at advancing the development of novel therapeutics for fibrotic diseases and osteoarthritis.

In August 2024, Mintz secured a summary judgement win for client Thomas Gad, Founder and President of Y-mAbs Therapeutics, Inc., against novel Section 16(b) short-swing trading claims in the Southern District of New York.

Mintz completed a $500 million senior secured credit facility for Arrowhead Pharmaceuticals on behalf of our client Sixth Street, enabling Arrowhead to fund innovation and growth opportunities across the company’s pipeline of RNAi therapeutics.

Mintz advised client ArriVent BioPharma, a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, on its upsized $175 million IPO on Nasdaq.

Mintz represented ArriVent Biopharma in a $155 Million Series B financing led by Sofinnova Investments and General Catalyst to fund studies of the company's EGFR kinase inhibitor furmonertinib. Members Ed Pease and Private Equity Practice Co-Chair Matthew Simpson led the Mintz team's work on the transaction.

When Daré Bioscience Operations, Inc. first became a Mintz client, it was a private health care company working to develop innovative product candidates in women’s reproductive health. Due to the significant expenses associated with product development and regulatory compliance for innovative drug, device, and combination products, the San Diego-based company sought to raise capital through entering the public markets. Since becoming a public company, Daré Bioscience has in-licensed multiple exciting product candidates focused on women’s sexual health, vaginal health, fertility, and contraception and prioritized a goal of achieving FDA marketing approval for one or more products.

Mintz’s client received 100% of the fees we requested on his behalf and was awarded $50,000 in sanctions when the arbitrator concluded the company’s counterclaims were frivolous.

Mintz litigators achieved a complete victory on behalf of our client Keryx Biopharmaceuticals in a putative securities class action case seeking over $100 million in damages.

Mintz and Licensing & Collaborations Practice Member John Cheney have represented BeiGene in numerous licensing transactions, including strategic collaborations with Amgen, Mirati Therapeutics, and Celgene, among others.

Mintz successfully achieved a nine figure arbitration award on behalf of a Boston-based biotechnology company before the International Chamber of Commerce.

Mintz is advising Vicarious Surgical Inc., a robotics company developing technology that combines human-like surgical robots and virtual reality to perform minimally invasive surgery, in a pending merger with special purpose acquisition company D8 Holdings Corp. that is expected to deliver up to $460 million in gross proceeds.

Check out UNITED NOTIONS, a new report on M&A activity in the life sciences sector. Produced in collaboration with Mergermarket, the report provides a comprehensive look at the health of deal activity in the industry and an insightful view of current trends as compared to a year ago.

Mintz analyzed PitchBook data to produce an in-depth report on the record rise in special purpose acquisition company (SPAC) fundraising in the US since 2020 and the recent increase in SPAC merger activity. We also explore how SPACs could evolve and litigation challenges to SPAC IPOs and transactions.

Mintz is acting as legal advisor to Quantum-SI Incorporated, developer of a pioneering semiconductor chip to sequence proteins, in its proposed business combination with HighCape Capital Acquisition Corp., a special purpose acquisition company (SPAC) sponsored by growth equity investment firm HighCape Capital LP.

Mintz served as legal advisor to Butterfly Network Inc., an innovative digital health company, in its merger with Longview Acquisition Corp., a special purpose acquisition company (SPAC) sponsored by Glenview Capital Management, LLC.

Mintz represented ImmunoGen in a $200 million non-dilutive royalty transaction of its interest in Kadcyla with funds managed by TPG Special Situation Partners.

In the first transaction of its kind, Mintz represented Intarcia Therapeutics in two synthetic royalty financings with an equity conversion option valued at $5.5B for ITCA 650.

Mintz represented ARIAD Pharmaceuticals in a synthetic royalty financing in which PDL BioPharma agreed to provide up to $200 million in revenue interest financing to ARIAD in exchange for royalties on worldwide net revenues of Iclusig (ponatinib).

Mintz represented Spero Therapeutics, a clinical-stage biopharmaceutical company developing treatments for drug-resistant bacterial infections, in a September 2020 underwritten public offering that netted $80 million in gross proceeds before the deduction of underwriting discounts and commissions.

Mintz advised Glia, LLC on its successful bid to obtain orphan drug status from the FDA for its topical gel to treat ocular Graft-versus-Host Disease. The disease can affect stem cell or bone marrow transplant recipients and cause intense eye pain, ocular degeneration, and blindness.

Mintz represented Massachusetts General Hospital and Partners HealthCare in a deal that enables them to monetize part of their royalty interests in Entyvio, an antibody used to treat digestive diseases, to invest in research. Royalty Pharma paid $94 million in the true sale roll-up transaction.

Mintz and Mergermarket produced a comprehensive report on recent M&A activity in the life sciences sector. We asked 100 US-based executives to share what motivated their latest transaction and their post-closing integration experiences.

Mintz’s E-Data Consulting Group counseled a large physician’s network and nonprofit hospital in complex negotiations with the Federal Trade Commission in relation to a proposed merger with another midsize physician’s network and hospital.

Mintz successfully led a national diagnostics company through a series of informal investigative inquiries from the Department of Justice and formal responses to subpoenas issued by the Office of Inspector General.

Mintz provides ongoing counsel to global biotech company in e-data discovery in a series of nationwide product liability cases related to its global franchise of marketed products.

After a lender abandoned our client’s financing transaction over concerns related to COVID-19, Mintz negotiated a convertible note financing with another investor — providing the client with up to $25M to pursue commercialization of its lead product.

Mintz helped patent prosecution client Glycosyn defend its exclusive patent rights against the company's largest competitor, a global company selling infringing ingredients used in baby formula.

Mintz represented Synlogic in an $80 million financing from Ginkgo Bioworks and the parties' related collaboration to expand development of Synlogic’s Synthetic Biotic medicines. Mintz previously helped Synlogic raise over $200 million in capital, plus another $40 million through a reverse merger.

Mintz represented Vida Ventures on the $600 million fundraise for its Vida II fund, which will be used to further the firm’s life sciences platform. Founded less than two years ago, Vida now has approximately $1 billion under management.

After helping Spero raise over $200 million, Mintz represented the biopharmaceutical company in its collaboration with the Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis (Mtb).

Mintz advised biopharma company Spero Therapeutics on an agreement with Everest Medicines regarding the development and commercialization of a product to treat multidrug-resistant bacterial infections and option to license another.

Mintz secured dismissal of a securities fraud case against biopharmaceutical company Neurotrope. Mintz argued that securities laws do not require disclosure of the statistical methodology behind announced clinical trial results.

Mintz represented ImmunoGen, a maker of targeted anticancer therapeutics, in a transaction that netted $194 million. The deal provided ImmunoGen with cash and liquid assets in exchange for assigning certain royalty revenues for the breast cancer treatment Kadcyla to TPG Special Situations Partners.

In July 2018 Mintz represented Spero Therapeutics, a multi-asset clinical stage biopharmaceutical company, in its underwritten public offering. The offering included 3,780,000 shares of its common stock and 2,220 shares of its non-voting Series A Convertible Preferred Stock, with the gross proceeds to Spero being $75M prior to the deduction of any underwriting discounts and commissions.

Mintz steered precision health company Quanterix Corporation through a $73.7 million initial public offering (IPO). The firm’s Securities & Capital Markets Practice advised Quanterix on the Securities and Exchange Commission review process as well as pricing and timing of the offering.

In federal and state cases alleging a large pharmaceutical client and its co-developer failed to adequately warn regarding the risk of personal injury, Mintz delivered wins on every substantive issue, in every case, in every jurisdiction.

Professionals in Mintz's Patent Prosecution & Strategic Counseling Practice advise Roche Molecular Systems on various patent matters. Mintz has managed the client’s patent portfolio since Roche Molecular acquired Ariosa Diagnostics and its non-invasive prenatal test “Harmony.

For Kowa Pharmaceuticals and Nissan Chemical, Mintz sued nine generic drug makers that had filed Abbreviated New Drug Applications (ANDA) with the FDA. The court upheld the validity and infringement of all asserted claims in two patents for the cholesterol drug Livalo®.

Mintz serves as general counsel to a privately held pharmaceutical R&D company focused on inflammatory, metabolic, and affective disorders. Mintz handles the company’s corporate, transactional, and IP work, including supporting the company’s preclinical and clinical research program.

Mintz has represented oncology-focused biotherapeutic company Inhibrx LP since its inception. Mintz attorneys have advised Inhibrx on licensing deals and financing deals involving unusual corporate and tax structuring and international aspects.

Mintz secured two MA federal court wins and one at the First Circuit for Vertex Pharmaceuticals, Inc. and several senior executives in a securities case about clinical trial result disclosures. The decision clarified the First Circuit standard for pleading scienter in securities fraud cases.

Mintz represented BeiGene, Ltd. in its global strategic collaboration with Celgene Corporation to develop and commercialize BeiGene’s cell death protein 1 (PD-1) inhibitor tislelizumab (BGB-A317) for patients with solid tumor cancers. Mintz also assists BeiGene with licensing transactions.

Mintz represented clinical-stage biopharmaceutical company Naurex Inc., which develops therapies for central nervous system disorders, in its acquisition by global pharmaceutical company Allergan PLC for $560 million plus potential milestone payments. Naurex’s platform was spun out into a new company.

Mintz is defending a major diagnostics company in a False Claims Act qui tam case filed by a former employee. The Department of Justice declined to intervene in the case, which involves allegations of managed care fraud. Mintz has filed a motion to dismiss and objections to discovery request

Mintz secured a full release of a biopharmaceutical company in a Louisiana state court case over alleged inflated drug price reporting. The client agreed to a nuisance value settlement of the case, resolving claims its actions cost the state’s Medicaid program more than $20 million.

Mintz provides FDA, data privacy, and clinical compliance advice to a publicly traded biotechnology company developing nucleic acid therapeutic candidates for rare genetic diseases, including Huntington’s disease and Duchenne Muscular Dystrophy. Mintz also helped the client expand its R&D program.

Mintz is helping a manufacturer and distributor of device systems used in wound treatment pursue Medicare and Medicaid coverage options throughout the country, including negotiating coding. Mintz attorneys met with the Centers for Medicare & Medicaid Services (CMS) regarding scope of coverage.

Mintz serves as national trial and coordinating counsel in two mass tort litigations against a surgeon involved in the design of two implantable orthopedic devices. An early trial result facilitated a national settlement that resolved most of the individual cases in one mass tort.

Mintz successfully mediated a dispute relating to medical device company Invivo Corp.’s retention of an $850,000 holdback reserve in its acquisition of Hologic, Inc.’s Sentinelle, an MRI coil product line. Mintz argued that Invivo suffered monetary losses due to Hologic’s breaches and inaccuracies.

Mintz served as national coordinating and lead trial counsel for a Fortune 500 medical device company in products liability mass torts. Mintz used a national settlement program in one litigation. Several published appellate decisions in another led to dismissals and favorable settlements.

Mintz served on national trial teams for a major pharmaceutical company in defending over 50,000 individual lawsuits, federal multidistrict litigation, and statewide coordinated proceedings alleging personal injury and wrongful death. Mintz's trial results facilitated the $4.85 billion settlement.

Mintz helped a digital health company develop corrective actions following a manufacturing inspection related to its Class 1 medical device. After the FDA deemed the company’s health tracking mobile application a regulated device, Mintz submitted an advocacy position paper to the agency.

Mintz protected clients’ patents related to the cholesterol drug Livalo®. Mintz defended against three IPRs filed by generic manufacturers that had filed Abbreviated New Drug Applications (ANDA) with the FDA and secured Patent Trial and Appeal Board denials of institution of the generic companies’ IPR petitions.

Mintz helped women’s reproductive health care company Daré Bioscience Operations, Inc. become a wholly owned subsidiary of Cerulean and a publicly traded company named Daré Bioscience, Inc. The innovative deal utilized a variation of a reverse merger into a publicly traded fallen-angel.

Mintz’s work for synthetic biotic company Synlogic Inc. has included raising over $100 million in three VC financing rounds. Mintz attorneys also helped Synlogic form a multiyear global R&D collaboration with AbbVie and raise more than $40 million in an IPO via a reverse merger with Mirna Therapeutics.